Chiglitazar for fatty liver-related cirrhosis
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests if a medication called Chiglitazar (a type of insulin sensitizer) is safe and effective for people with cirrhosis caused by metabolic-associated fatty liver disease (MAFLD). It may help reduce liver scarring and improve metabolic health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have cirrhosis (scarring of the liver) due to fatty liver disease and at least one or two metabolic issues like obesity or type 2 diabetes.
- You have not had a recent weight loss of 10% or more if diagnosed by liver biopsy during screening.
- You do not have other liver diseases (like hepatitis or alcoholic liver disease).
- You are not currently using certain diabetes or weight-loss medications (like TZDs, GLP-1 agonists, or insulin) within the last 6 months.
- You have not had major heart or blood vessel events in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests strategies to prevent cirrhosis in people with metabolic fatty liver disease and early to moderate liver scarring. It aims to find better ways to stop liver damage from getting worse.
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
This trial tests a new medication called ACT500 for people with fatty liver disease (MASLD). The goal is to see if it is safe and how the body processes it. You may be able to join if you have at least 10% liver fat, some liver scarring or damage, and certain metabolic risk factors like being overweight or having prediabetes.
This trial tests whether a medication called Chiglitazar Sodium, combined with lifestyle changes like diet and exercise, can help reverse prediabetes (higher-than-normal blood sugar that isn't yet diabetes). If you have prediabetes, this study may help prevent you from developing type 2 diabetes.
This trial tests whether adding a new diabetes medication called chiglitazar to your current SGLT-2 inhibitor can help lower your blood sugar better. You may qualify if your blood sugar is still too high despite taking an SGLT-2 inhibitor, and this study could help find better ways to control your diabetes.
This trial tests how the body processes saroglitazar in people with moderate liver impairment caused by cholestatic liver disease. The goal is to ensure the drug is safe and dosed correctly for this group.
Hear when a new Metabolic Dysfunction-associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.